Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

  1. United States Stocks
  2. •

    Healthcare
  3. •

    Biotechnology
Y

Savara Inc.

YB4P GF

YB4P GFSavara Inc.DEGF
FIGI: BBG000MD2WN8

Company Description

CEO
Mr. Matthew Pauls J.D., M.B.A.
Full Time Employees
28
Sector
Healthcare
Industry
Biotechnology
Address
Building III Austin TX United States 78746
IPO Date
Apr 28, 2017
Website
www.savarapharma.com
Business
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.

3.50

EUR
-0.04
(-1.13%)

Company News

  • Dow Jones Newswires

    a month ago

    Savara 2Q Loss $11.4M >SVRA

  • Dow Jones Newswires

    2 months ago

    Savara Shares Near 52-Week High After $80M Offering Prices

  • Dow Jones Newswires

    2 months ago

    Savara Prices Share Offering at $3 a Share

  • Dow Jones Newswires

    6 months ago

    Savara 4Q Loss/Shr 7c >SVRA

Next Earnings
November 8
Dividend Date
April 28
Held by Insiders
1.96%
Held by Institutions
58.83%
Short % of Float
1.65%
YTD Yield
134.28%
3Y Yield
233.96%
5Y Yield
-62.22%
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
129
118
108
Cash, Cash Equivalents & STI
126
115
105
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
5
6
Payables & Accruals
3
4
4
ST Debt
0
0
0
Deferred Revenue
- -
- -
- -
Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
0
0
0
LT Borrowings
26
26
26
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
114
114
114
Market Capitalization
177
222
365
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
-0.13
-0.07
-0.07
-0.07
-0.32
2022
-0.05
-0.06
-0.07
-0.07
-0.25
2023
-0.07
-0.07
- -
- -
- -
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
- -
- -
- -
Net Income, GAAP
-27.85%
-14.19%
11.63%
Free Cash Flow
-31.21%
-5.19%
12.50%
Total Cash Common Dividend
- -
- -
- -
Total Equity
-65.47%
9.59%
-25.00%